Factors associated with the successful modification of antiretroviral therapy

AIDS

Volumn 14, Issue 5, 2000, Pages 491-497

  Weidle, Paul J ^a,b   Lichtenstein, Kenneth A ^c   Moorman, Anne C ^a   Von Bargen, Jennifer C ^a   Greenberg, Kenneth S ^c   Palella Jr , Frank J ^d   Holmberg, Scott D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c ROSE MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Genotypic; Modification; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AGED; ANTIVIRAL ACTIVITY; ARTICLE; COHORT ANALYSIS; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0034073039     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003310-00004     Document Type: Article

References (23)

1. 1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. 2. State-of-the-Art Conference on Azidothymidine Therapy for Early HIV Infection. Am J Med 1990, 89:335-344.
3. 3. Sande MA, Carpenter CCJ, Cobbs G, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of the-art conference. JAMA 1993, 270:2583-2589.
4. 4. Carpenter CCJ, Fischl MA, Hammer SC, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996, 276:146-154.
5. 5. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
6. 6. Brun-Vezinet F, Boucher C, Loveday C, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997, 330:983-990.
7. 7. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multi-drug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998, 128:906-911.
8. 8. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995, 171:1172-1179.
9. 9. Rey D, Hughes M, Pi J, Winters M, Merigan RC, Katzenstein DA. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. J Acquired Immune Defic Syndr Hum Retrovirol 1998, 17:203-208.
10. 10. Carpenter CCJ, Fischl MA, Hammer SC, et al. Antiretroviral therapy for HIV infection. Updated recommendations of the International AIDS Society - USA panel. JAMA 1997, 277:1962-1969.
11. 11. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA panel. JAMA 2000, 283:381-390.
12. 12. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at http://www.hivatis.org. Accessed 28 January 2000. [Originally published in MMWR 1998, 47(No. RR-5):1-82.]
13. 13. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC, and the Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. [Abstract] In: Program and Abstracts of 3rd International Workshop on HIV Drug Resistance and Treatment Strategies. San Diego, CA: 61. Available from International Medical Press, Atlanta, GA, USA.
14. 14. Durant J, Clevenbaugh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353:2195-2199.
15. 15. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. JAMA 1998, 279:1984-1991.
16. 16. Schinarzi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1996, 4:95-107.
17. 17. Deeks SG, Abrams Dl. Genotypic-resistance assays and antiretroviral therapy. Lancet 1997, 349:1489-1490.
18. 18. Condra JH. Resisting resistance: maximizing the durability of antiretroviral therapy. Ann Intern Med 1998, 128: 951-954.
19. 19. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998, 280:1871-1873.
20. 20. Fallon J. Time to genotype for selection of antiretroviral regimens in previously treated patients? Lancet 1999, 353: 2173-2174.
21. 21. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
22. 22. Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART), Lancet 1998, 351:723-724.
23. 23. Colgrove R, Japour A. A combinatorial edge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Res 1999, 41:45-56.